Friday, November 11, 2016

BRIEF-UCB's anti-epileptic drug VIMPAT receives positive opinion by EU CHMP

* UCB's anti-epileptic drug VIMPAT (lacosamide) receives positive opinion by EU CHMP as

monotherapy for patients with partial-onset seizures

Source text: http://bit.ly/2fIeuV8

Further company coverage:

(Gdynia Newsroom)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)